menu
    • menu

    Company profile for Taiho Pharmaceutical

    NEW Drugs in Dev: 15
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    In 1969, Taiho Pharmaceutical’s first president, Yukio Kobayashi, visited the former Soviet Union for business discussions on Pantocrin Injection, a drug to ameliorate general malaise for which demand had suddenly started to increase at the time.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Taiho Pharmaceuticaljapan Flag
    Country
    Country
    Japan
    Address
    Address
    1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444
    Telephone
    Telephone
    +81-3-3294-4527
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.taiho.co.jp/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Accepts Zipalertinib NDA for EGFR Exon 20 NSCLC Cancer
    FDA Accepts Zipalertinib NDA for EGFR Exon 20 NSCLC Cancer

    28 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-28/us-food-and-drug-administration-accepts-new-drug-application-for-zipalertinib-for-the-treatment-of

    PHARMIWEB
    28 Apr 2026
    Share Share
    Taiho Ventures Celebrates 10th Anniversary
    Taiho Ventures Celebrates 10th Anniversary

    15 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/taiho-ventures-llc-celebrates-10th-anniversary-302742512.html

    PR NEWSWIRE
    15 Apr 2026
    Share Share
    Taiho, Cullinan Start NDA Submission For Zipalertinib In NSCLC
    Taiho, Cullinan Start NDA Submission For Zipalertinib In NSCLC

    20 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/taiho-oncology-taiho-pharmaceutical-and-cullinan-therapeutics-initiate-rolling-submission-of-new-drug-application-to-us-food-and-drug-administration-for-zipalertinib-for-treatment-of-locally-advanced-or-metastatic-non-small-cel-302621302.html

    PR NEWSWIRE
    20 Nov 2025
    Share Share
    Taiho Pharma Opts For Exclusive License Of Casdatifan In Japan
    Taiho Pharma Opts For Exclusive License Of Casdatifan In Japan

    19 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251019482380/en/Taiho-Pharmaceutical-Exercises-Option-for-an-Exclusive-License-to-Casdatifan-in-Japan-and-Certain-Territories-in-Asia

    BUSINESSWIRE
    19 Oct 2025
    Share Share
    Taiho’s Inqovi Combo sNDA Accepted By US FDA For AML
    Taiho’s Inqovi Combo sNDA Accepted By US FDA For AML

    09 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/taiho-oncology-and-taiho-pharmaceutical-announce-us-fda-acceptance-of-supplemental-new-drug-application-for-inqovi-in-combination-with-venetoclax-to-treat-patients-with-acute-myeloid-leukemia-302501545.html

    PR NEWSWIRE
    09 Jul 2025
    Share Share
    Taiho’s DMD asset misses in phase 3 trial
    Taiho’s DMD asset misses in phase 3 trial

    09 Jul 2025

    // PRESS RELEASE

    https://www.taiho.co.jp/en/release/2025/20250708.html

    PRESS RELEASE
    09 Jul 2025
    Share Share

    ABOUT THIS PAGE

    Contact Taiho Pharmaceutical and get a quotation

    Taiho Pharmaceutical is a supplier offers 9 products (APIs, Excipients or Intermediates).

    Find Tipiracil Hydrochloride bulk with DMF offered by Taiho Pharmaceutical

    Find Trifluridine bulk with DMF offered by Taiho Pharmaceutical

    Find 2 1H-Pyridinone 5-Chloro-4-Hydroxy bulk offered by Taiho Pharmaceutical

    Find 3-2,4-Dimethoxybenzylidene-Anabaseine bulk offered by Taiho Pharmaceutical

    Find Suplatast Tosilate bulk offered by Taiho Pharmaceutical

    Find Tac 101 bulk offered by Taiho Pharmaceutical

    Find Tegafur bulk offered by Taiho Pharmaceutical

    Find TAS-103 bulk offered by Taiho Pharmaceutical

    Find Gimeracil bulk offered by Taiho Pharmaceutical

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search